Long Term Durability and Safety of Dual IO in NSCLC

 

Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care
M

USC Updates on RT for mNSCLC: Consolidative Local Therapy

By Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care FEATURING Megan Daly
By Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care FEATURING Megan Daly
81 views
July 1, 2021
0 Comments
Login to view comments. Click here to Login
Long Term Durability and Safety of Dual IO in NSCLC
09:22
Luis Paz-Ares

2021 ASCO Review on Nivo + Ipi vs. Chemo as 1L Treatment for Advance…

09:18
Filippo de Marinis

1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 Cycles) in mNSC…

11:11
Tom John

2021 ASCO Update on 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alon…

04:06
ecancer

1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: R…

Feat. D. Carbone
05:22
ecancer

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

Feat. S. Peters
07:25
ecancer

ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials

Feat. L. Raez
31:18
UAB Medicine Hematology and Oncology Highlights 2021

2021 ASCO Updates on Lung Cancer: (Neo)adjuvant Therapy, Metastatic …

Feat. A. Hegde
19:26
Mariam Alexander

Standard 1L Treatment of Advanced NSCLC in 2021: IO Combination &…

20:10
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

Epidemiological Shifts in Lung Cancers: Trends in Treatment and Diag…

Feat. E. David
14:53
Northwestern Medicine Oncology and Hematology

Serum Proteomic Signature & Advanced NSCLC: Can It Be Used as an…

Feat. Y. Chae
36:33
CECOG Academy

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

Feat. C. Zielinski
17:55
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

USC Updates on RT for mNSCLC: Consolidative Local Therapy

Feat. M. Daly
61:10
Scripps MD Anderson Cancer Center

Advances in the NSCLC Treatment

Feat. M. Kosty
21:04
2022 West Oncology Conference

Metastatic NSCLC: Approaches and Updates

Feat. J. Porter
37:58
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2022

Practical Approach to Selection of Frontline Therapy in NSCLC Withou…

Feat. M. Johnson
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

Feat. J. Sands
24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

Feat. J. Sands
01:18
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

Feat. B. Besse
13:01
Nebraska Oncology Society

ASCO 2022 on Immunotherapy Updates in Advanced NSCLC

Feat. J. Brahmer
09:18
ASCO 2022 Conference Coverage

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

Feat. L. Paz-Ares
01:46
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

Feat. L. Paz-Ares
06:03
Penn Medicine Abramson Cancer Center

Penn Medicine mNSCLC Updates

Feat. M. Marmarelis
10:59
ASCO 2022 Conference Coverage

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

Feat. L. Paz-Ares
01:24
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMa…

Feat. L. Paz-Ares
16:37
Lung Cancer Europe (LuCE)

ASCO 2022 Early Stage NSCLC Updates

Feat. J. Naidoo
47:32
Aaron Franke

1L Therapy for Advanced/Metastatic PD-L1 Negative (TPS <1%) NSCLC

10:17
WCLC 2022 Conference Coverage

WCLC 2022 on Modifiable Biomarkers of Response to Immune Checkpoint …

Feat. D. Spakowicz
01:43
WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Modifiable Biomarkers of Response to …

Feat. D. Spakowicz
17:29
ILCC 2022 Conference Coverage

Neoadjuvant vs. Adjuvant Immunotherapy From the Surgeon's Persp…

Feat. T. Mitsudomi
07:36
ESMO 2022 Conference Coverage

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in P…

Feat. T. John
23:21
Giuseppe Banna

Neoadjuvant Chemotherapy and Immunotherapy for NSCLC

08:17
Nicolas Girard

Neoadjuvant Nivo + Platinum-Doublet Chemo vs. Chemo for Resectable (…